Generics

Delzicol delayed-release capsules have a market value of roughly $130 million, according to February 2019 IQVIA data.

Clobazam tablets have a market value of roughly $479 million, according to March 2019 IQVIA data.

Teva is expected to launch its generic of Gilead's Truvada one year earlier than expected.

Tarceva tablets have a market value of $202 million, according to IQVIA data as of February 2019.

The Association for Accessible Medicines said the Food and Drug Administration's guidance on naming biological products delays the development of biosimilars.

The Association for Accessible Medicines is proposing five areas of reform related to intellectual property and its impact on generic drug availability in the wake of the committee's recent hearing.

Fosaprepitant for injection, 150 mg single-dose vial, had a market value of approximately $312 million for the year ended March 2019, per IQVIA data.

Letairis had a market value of roughly $247 million as of February 2019, according to IQVIA data.